Partnering with industrials is the way to succeed in technology development to transform an invention into a successful product for the benefit of patients and public health. The Institut Pasteur and its industrial partners are collaborating to reach this goal.
Bringing an innovative solution to patient’s unmet needs is a challenge that today no single organization can achieve. Academic and industrials must now rapidly unite their expertise to provide medical, scientific and technological responses for patient’s health.
With past and current fruitful research partnerships, the Institut Pasteur is intensifying its visibility and availability to future industrial partners, from startups to large groups.
What Institut Pasteur offers
By collaborating with the Institut Pasteur, industry partners can benefit from its extended diversity fields of research.
Joint applications can be made to national and international calls for proposals (IMI, H2020, NIH, CEPI, etc.).
Companies with R&D activity in France are eligible for 60% research tax credit
Acces to the institute’s cutting-edge technical facilities, such as the Technological Research Platforms (DTPS), the Bioinformatics and biostatistics Hub,
the Medical Center and the Center for Translational Science (CRT) as well as the Microbiology Technology Institute Bioaster.
And much more if you are part of a strategic alliance partnership
Created in April 2012 by the Institut Pasteur and Lyonbiopole health competitiveness cluster, following the initiative of the French government, Bioaster Technology Research Institute (TRI) is working to develop a unique technological and innovative model to support the latest challenges in microbiology, in particular to:
Fight antimicrobial resistance
Improve the safety and efficacy of vaccines. Quickly diagnose infections at patient‘s bedside. Take full advantage of human and animal microbiota.
The aim of Bioaster is to boost the development of medical and nutritional solutions for human and animal health.
Bioaster has the support of high-profile academic and industrial partners. Since it was set up, it has coordinated over 53 research projects with 25 academic partners and 26 industry partners (source: Bioaster).
In between the phases of the acquisition of knowledge and providing a solution for the patient, Bioaster wants to act as a bridge between the academic and private spheres, provide a technological added value in microbiology and is an agile and collaborative organisation that reduces the risks associated with innovation.
The current available patents for licensing and tech transfer are depicted below. Please consult each of these documents of interest for more details to fetch out technologies which would meet with your needs.